Pam2csk4

Summary

Pam2CSK4 (dipalmitoyl-S-[2,3-bis(palmitoyloxy)propyl]cysteine-serine-lysine4) is a synthetic diacylated lipopeptide used as a TLR2/TLR6 agonist in immunological research. It serves primarily as an adjuvant and innate immune stimulator in preclinical studies, vaccine research, and as a tool compound to study pattern recognition receptor biology.

Mechanism of Action

Synthetic diacylated lipopeptide that acts as a TLR2/TLR6 heterodimer agonist. Mimics bacterial lipoproteins, activating innate immune signaling pathways including NF-κB and MAPK cascades, leading to pro-inflammatory cytokine production and immune cell activation.

Routes of Administration

Goals & Uses

• Vaccine adjuvantVaccinologyModerate
• Mucosal immunity inductionImmunologyModerate
• TLR2/TLR6 pathway research toolBasic ResearchHigh
• Anti-infective prophylaxis (research)Infectious DiseaseLow
• Innate immune activationImmunostimulationHigh

Contraindications

• Systemic administration in inflammatory conditionsClinicalHigh
• Human therapeutic useRegulatory/safetyHigh

Adverse Effects

• Sepsis-like syndrome (high dose)Systemic ToxicityRare
• Pro-inflammatory cytokine release (TNF-α, IL-6, IL-12)Systemic Immune ReactionCommon
• Fever / pyrogenicitySystemic Immune ReactionUncommon
• Local inflammation at injection siteLocal ReactionCommon

Drug Interactions

• Immunosuppressants (e.g., corticosteroids, tacrolimus)Moderate
• Other TLR agonistsModerate

Population Constraints

• Immunocompromised animals/modelsPreclinicalRelative
• Human subjectsRegulatory/SafetyAbsolute

Regulatory Status

• European UnionUnapprovedResearch reagent only; not approved by EMA.
• United StatesUnapprovedResearch reagent only; not approved by FDA for any therapeutic indication.
• United KingdomUnapprovedResearch reagent only; not approved by MHRA.

Not approved for human therapeutic use in any jurisdiction. Used exclusively as a research reagent and in preclinical/experimental vaccine adjuvant studies.

Evidence & Sources

No sources recorded yet.